Q3 2022 Earnings Forecast for Repligen Co. (NASDAQ:RGEN) Issued By KeyCorp

Repligen Co. (NASDAQ:RGENGet Rating) – Equities researchers at KeyCorp lowered their Q3 2022 earnings per share (EPS) estimates for shares of Repligen in a research report issued on Tuesday, August 2nd. KeyCorp analyst P. Knight now anticipates that the biotechnology company will earn $0.67 per share for the quarter, down from their prior forecast of $0.70. KeyCorp currently has a “Overweight” rating and a $260.00 price target on the stock. The consensus estimate for Repligen’s current full-year earnings is $3.10 per share. KeyCorp also issued estimates for Repligen’s Q4 2022 earnings at $0.65 EPS.

RGEN has been the topic of several other reports. SVB Leerink upped their target price on Repligen from $220.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday. Craig Hallum dropped their target price on Repligen from $286.00 to $274.00 in a report on Thursday, April 28th. Stephens raised their target price on Repligen from $220.00 to $275.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, UBS Group assumed coverage on Repligen in a report on Wednesday, July 20th. They set a “buy” rating and a $213.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $276.00.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $243.30 on Thursday. The stock has a market capitalization of $13.24 billion, a P/E ratio of 87.83 and a beta of 1.07. Repligen has a 1-year low of $137.21 and a 1-year high of $327.32. The business has a fifty day moving average price of $173.67 and a 200 day moving average price of $173.67.

Repligen (NASDAQ:RGENGet Rating) last issued its quarterly earnings data on Tuesday, August 2nd. The biotechnology company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.19. The firm had revenue of $207.63 million during the quarter, compared to analysts’ expectations of $189.06 million. Repligen had a return on equity of 11.28% and a net margin of 20.47%. The firm’s quarterly revenue was up 27.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.79 EPS.

Insiders Place Their Bets

In other news, Director Karen A. Dawes sold 14,715 shares of the firm’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $150.51, for a total value of $2,214,754.65. Following the transaction, the director now owns 76,532 shares in the company, valued at $11,518,831.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Karen A. Dawes sold 14,715 shares of the firm’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $150.51, for a total value of $2,214,754.65. Following the transaction, the director now owns 76,532 shares in the company, valued at $11,518,831.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO James Bylund sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $240.40, for a total value of $480,800.00. Following the completion of the transaction, the chief operating officer now owns 9,733 shares in the company, valued at approximately $2,339,813.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,517 shares of company stock worth $8,095,955. 1.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Repligen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Royce & Associates LP grew its stake in shares of Repligen by 41.0% in the second quarter. Royce & Associates LP now owns 127,219 shares of the biotechnology company’s stock valued at $20,660,000 after buying an additional 37,019 shares in the last quarter. Securian Asset Management Inc. grew its stake in shares of Repligen by 2.5% in the second quarter. Securian Asset Management Inc. now owns 4,700 shares of the biotechnology company’s stock valued at $763,000 after buying an additional 115 shares in the last quarter. State of New Jersey Common Pension Fund D grew its stake in shares of Repligen by 2.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 31,786 shares of the biotechnology company’s stock valued at $5,162,000 after buying an additional 901 shares in the last quarter. Northwestern Mutual Investment Management Company LLC grew its stake in shares of Repligen by 1.1% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 8,630 shares of the biotechnology company’s stock valued at $1,402,000 after buying an additional 90 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Repligen by 6.2% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 167,013 shares of the biotechnology company’s stock valued at $27,123,000 after buying an additional 9,802 shares in the last quarter. Institutional investors and hedge funds own 86.82% of the company’s stock.

About Repligen

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.